Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) is a pharmaceutical drug with 21 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
21 of 21 finished
0.0%
0 ended early
0
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Eylea Post Marketing Surveillance(PMS)
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
Clinical Trials (21)
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Eylea Post Marketing Surveillance(PMS)
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Aflibercept in Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
Study for Collection of Aflibercept Data in Routine Practice
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21